<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00040209</url>
  </required_header>
  <id_info>
    <org_study_id>020236</org_study_id>
    <secondary_id>02-N-0236</secondary_id>
    <nct_id>NCT00040209</nct_id>
  </id_info>
  <brief_title>JP-1730 to Treat Parkinson's Disease</brief_title>
  <official_title>Alpha-2 Adrenergic Antagonist Treatment of Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of an experimental drug called JP-1730 on Parkinson's&#xD;
      disease symptoms and on dyskinesias (involuntary movements) that develop as a result of&#xD;
      long-term treatment with levodopa. JP-1730 affects chemical messengers believed to affect&#xD;
      Parkinson's disease symptoms.&#xD;
&#xD;
      Patients between 30 and 80 years of age with relatively advanced Parkinson's disease may be&#xD;
      eligible for this 3-phase study.&#xD;
&#xD;
        -  Phase 1 - Baseline evaluation&#xD;
&#xD;
      Participants will be evaluated with a medical history, physical examination, detailed&#xD;
      neurologic evaluation, routine blood tests, urinalysis and an electrocardiogram. They will&#xD;
      also have a 24-hour holter monitor (heart monitoring) and cardiology consultation. A chest&#xD;
      X-ray and MRI or CT scan of the brain will be done if needed. Patients will, if possible,&#xD;
      stop taking all antiparkinsonian medications except levodopa (Sinemet) for one month before&#xD;
      the study begins and throughout its duration. (If necessary, patients may use short-acting&#xD;
      dopamine agonists, such as Mirapex and Requip.)&#xD;
&#xD;
        -  Phase 2 - Dose Finding Phase&#xD;
&#xD;
      For 2 to 3 days, patients will be admitted to the NIH Clinical Center for a levodopa (a&#xD;
      dopamine agonist) dose-finding procedure. For this procedure, patients stop taking Sinemet&#xD;
      and instead have levodopa, and subsequently apomorphine, infused through a vein. During the&#xD;
      infusions, the drug dose is increased slowly until either 1) parkinsonian symptoms improve,&#xD;
      2) unacceptable side effects occur, or 3) the maximum study dose is reached. Symptoms are&#xD;
      monitored frequently to find the optimal dose. (Patients who have had dosing infusions in the&#xD;
      last 3 months will not have to undergo this phase of the study.)&#xD;
&#xD;
        -  Phase 3 - Active Study Phase&#xD;
&#xD;
      Within 3 months of the dose-finding phase, treatment will begin. Patients will receive seven&#xD;
      doses of JD-1730 or placebo (an inactive substance) via puffs from an oral spray together&#xD;
      with levodopa infusions over a 3-week period. The doses are given on days 1, 2, and 3 of the&#xD;
      first week and then approximately twice a week for the next 2 weeks. For these doses,&#xD;
      patients are hospitalized 4 days the first week and 2 days each for the next 2 weeks. All&#xD;
      participants will receive placebo at some time during the study, and a few patients, selected&#xD;
      at random, will receive only placebo the entire 3 weeks. The procedure for the infusions is&#xD;
      the same as that for the dose-finding phase, with frequent evaluation of symptoms. Also,&#xD;
      small blood samples are drawn up to three times each study day. At the end of the third week,&#xD;
      patients will be discharged from the hospital. Their anti-parkinsonian medications may be&#xD;
      readjusted, as needed. Patients will be contacted 2 weeks after the end of the study for a&#xD;
      check on side effects and, if necessary, will be scheduled for a follow-up evaluation at the&#xD;
      clinic.&#xD;
&#xD;
      In addition to the above procedures, patients will be asked to have an optional lumbar a&#xD;
      puncture (spinal tap) on the first and last days of the study to measure various brain&#xD;
      chemicals and drug levels that cannot be measured in blood and urine. For this procedure, a&#xD;
      local anesthetic is given and a needle is inserted in the space between the bones (vertebrae)&#xD;
      in the lower back. About 2 tablespoons of fluid is collected through the needle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the effects of selective alpha-2 adrenergic&#xD;
      receptor antagonism on the severity of parkinsonian signs and dopaminomimetic drug-associated&#xD;
      motor response complications in patients with mild to moderately advanced Parkinson's&#xD;
      disease. In a controlled proof-of-principle clinical study, the acute efficacy of JP-1730&#xD;
      will be assessed through the use of validated motor function scales. Safety will be monitored&#xD;
      by means of frequent clinical evaluations and laboratory tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date>July 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Parkinson Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JP 1730</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Levodopa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Apomorphine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
        Patients who meet all of the following inclusion criteria at Day 0 will be eligible to&#xD;
        participate in the study:&#xD;
&#xD;
        Patient is between the ages of 30 and 80;&#xD;
&#xD;
        Patient has an intact oral mucosa;&#xD;
&#xD;
        Patient has been diagnosed with idiopathic Parkinson's disease based on the presence of a&#xD;
        characteristic clinical history and neurologic findings;&#xD;
&#xD;
        Patient has relatively advanced disease with levodopa-associated motor response&#xD;
        complications, including peak-dose dyskinesias and wearing-off fluctuations;&#xD;
&#xD;
        Patient is willing to adhere to protocol requirements as evidenced by written, informed&#xD;
        consent.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Patients meeting any of the following exclusion criteria either at Day 0 or during the&#xD;
        study will not be enrolled or will be immediately excluded from the study, as appropriate:&#xD;
&#xD;
        Patient has a history of any medical condition that can reasonably be expected to subject&#xD;
        the patient to unwarranted risk, including bronchospasm or lung disease, clinically&#xD;
        significant cardiac arrhythmias and/or myocardial ischemia; baseline bundle branch block or&#xD;
        QTc greater than 480 msec;&#xD;
&#xD;
        Patient has clinically significant laboratory abnormalities including liver enzyme&#xD;
        elevation greater than twice the upper limit of normal;&#xD;
&#xD;
        Patient is unable to be treated with levodopa/carbidopa alone or with a single, relatively&#xD;
        short-acting dopamine agonist, such as pramipaxole or ropinirole;&#xD;
&#xD;
        Patient is taking a prohibited concomitant medication;&#xD;
&#xD;
        Patient has not been using an adequate contraceptive method for the last 30 days, or is not&#xD;
        at least one year post-menopausal (if female);&#xD;
&#xD;
        Patient is pregnant or breastfeeding;&#xD;
&#xD;
        Patient is implanted with bilateral deep brain stimulators;&#xD;
&#xD;
        Patient has prior bilateral pallidotomy or other ablative surgeries for treatment of PD;&#xD;
&#xD;
        Patient has cognitive impairment (MMSE less than 25);&#xD;
&#xD;
        Patients with known history of chronic adrenal pituitary insufficiency, pituitary&#xD;
        insufficiency, or clinically significant laboratory abnormalities suggestive of adrenal&#xD;
        insufficiency, such as an elevated ACTH level;&#xD;
&#xD;
        Patient has an obvious oral mucosa abnormality;&#xD;
&#xD;
        Patient has participated in a clinical study with an investigational drug within the last&#xD;
        30 days;&#xD;
&#xD;
        Patient has a condition (such as active drug or alcohol abuse) that, in the opinion of the&#xD;
        investigators, would interfere with compliance or safety;&#xD;
&#xD;
        Patient is unwilling to sign an informed consent or to comply with protocol requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institute of Neurological Disorders and Stroke (NINDS)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chase TN, Oh JD, Blanchet PJ. Neostriatal mechanisms in Parkinson's disease. Neurology. 1998 Aug;51(2 Suppl 2):S30-5. Review.</citation>
    <PMID>9711978</PMID>
  </reference>
  <reference>
    <citation>Mizuno Y, Mori H, Kondo T. Parkinson's disease: from etiology to treatment. Intern Med. 1995 Nov;34(11):1045-54. Review.</citation>
    <PMID>8774962</PMID>
  </reference>
  <reference>
    <citation>Miyawaki E, Lyons K, Pahwa R, Tr√∂ster AI, Hubble J, Smith D, Busenbark K, McGuire D, Michalek D, Koller WC. Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol. 1997 Dec;20(6):523-30.</citation>
    <PMID>9403226</PMID>
  </reference>
  <verification_date>July 2005</verification_date>
  <study_first_submitted>June 21, 2002</study_first_submitted>
  <study_first_submitted_qc>June 21, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>JP 1730</keyword>
  <keyword>Dyskinesias</keyword>
  <keyword>Levodopa Infusion</keyword>
  <keyword>Apomorphine Infusion</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Parkinson Disease</keyword>
  <keyword>PD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Apomorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

